WO2005011642A1 - Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent - Google Patents
Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent Download PDFInfo
- Publication number
- WO2005011642A1 WO2005011642A1 PCT/BE2004/000111 BE2004000111W WO2005011642A1 WO 2005011642 A1 WO2005011642 A1 WO 2005011642A1 BE 2004000111 W BE2004000111 W BE 2004000111W WO 2005011642 A1 WO2005011642 A1 WO 2005011642A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- composition according
- fenofibrate
- lowering agent
- homocysteine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/567,407 US20070160663A1 (en) | 2003-08-05 | 2004-08-04 | Single unit pharmaceutical composition comprising a mixture of fenofibrate and a modified release form of a homocysteine reducing agent |
CA002534660A CA2534660A1 (en) | 2003-08-05 | 2004-08-04 | Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent |
EP04761472A EP1663174A1 (en) | 2003-08-05 | 2004-08-04 | Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE0300132 | 2003-08-05 | ||
BEPCT/BE03/00132 | 2003-08-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005011642A1 true WO2005011642A1 (en) | 2005-02-10 |
WO2005011642A9 WO2005011642A9 (en) | 2005-12-01 |
Family
ID=34109531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE2004/000111 WO2005011642A1 (en) | 2003-08-05 | 2004-08-04 | Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1663174A1 (en) |
CA (1) | CA2534660A1 (en) |
WO (1) | WO2005011642A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006007671A2 (en) * | 2004-07-22 | 2006-01-26 | Jallal Messadek | Therapeutically combinations |
WO2008095263A1 (en) * | 2007-02-09 | 2008-08-14 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
WO2009070211A1 (en) * | 2007-11-27 | 2009-06-04 | Abbott Cardiovascular Systems Inc. | Sustained release of apo a-i mimetic peptides and methods of producing them |
US7780990B2 (en) | 2005-02-15 | 2010-08-24 | Jallal Messadek | Combination therapeutic compositions and method of use |
US7786077B2 (en) | 2005-04-27 | 2010-08-31 | Jallal Messadek | Insulins combinations |
US8318805B2 (en) | 2004-11-10 | 2012-11-27 | Jallal Messadek | Modulation of nitric oxide synthases by betaines |
US8343947B2 (en) | 2003-07-15 | 2013-01-01 | Jallal Messadek | Therapeutic treatment |
WO2016050734A1 (en) * | 2014-09-30 | 2016-04-07 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Combinations of serotonin norepinephrine reuptake inhibitors and folate sources |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113134086A (en) * | 2020-01-20 | 2021-07-20 | 深圳市长卿医学研究院 | Pharmaceutical composition for reducing blood fat |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19910682A1 (en) * | 1999-03-10 | 2000-09-21 | Jutta Dierkes | Fibrate based preparation for treating hyperlipoproteinemia additionally contains vitamin or related compound, e.g. cobalamin or folic acid, to prevent the side effect of hyperhomocysteinemia |
WO2001056609A1 (en) * | 2000-02-03 | 2001-08-09 | Sabine Westphal | Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments |
US6465013B1 (en) * | 1999-07-12 | 2002-10-15 | Shaklee Corporation | Folic acid in solid dosage forms |
WO2003013501A1 (en) * | 2001-08-07 | 2003-02-20 | Laboratoires Smb Sa | Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it |
-
2004
- 2004-08-04 WO PCT/BE2004/000111 patent/WO2005011642A1/en not_active Application Discontinuation
- 2004-08-04 EP EP04761472A patent/EP1663174A1/en not_active Withdrawn
- 2004-08-04 CA CA002534660A patent/CA2534660A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19910682A1 (en) * | 1999-03-10 | 2000-09-21 | Jutta Dierkes | Fibrate based preparation for treating hyperlipoproteinemia additionally contains vitamin or related compound, e.g. cobalamin or folic acid, to prevent the side effect of hyperhomocysteinemia |
US6465013B1 (en) * | 1999-07-12 | 2002-10-15 | Shaklee Corporation | Folic acid in solid dosage forms |
WO2001056609A1 (en) * | 2000-02-03 | 2001-08-09 | Sabine Westphal | Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments |
WO2003013501A1 (en) * | 2001-08-07 | 2003-02-20 | Laboratoires Smb Sa | Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it |
Non-Patent Citations (1)
Title |
---|
DIERKES JUTTA ET AL: "Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate", ATHEROSCLEROSIS, vol. 158, no. 1, September 2001 (2001-09-01), pages 161 - 164, XP002288439, ISSN: 0021-9150 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8343947B2 (en) | 2003-07-15 | 2013-01-01 | Jallal Messadek | Therapeutic treatment |
WO2006007671A2 (en) * | 2004-07-22 | 2006-01-26 | Jallal Messadek | Therapeutically combinations |
WO2006007671A3 (en) * | 2004-07-22 | 2006-02-23 | Jallal Messadek | Therapeutically combinations |
US8318805B2 (en) | 2004-11-10 | 2012-11-27 | Jallal Messadek | Modulation of nitric oxide synthases by betaines |
US7780990B2 (en) | 2005-02-15 | 2010-08-24 | Jallal Messadek | Combination therapeutic compositions and method of use |
US7786077B2 (en) | 2005-04-27 | 2010-08-31 | Jallal Messadek | Insulins combinations |
WO2008095263A1 (en) * | 2007-02-09 | 2008-08-14 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
AU2008213744B2 (en) * | 2007-02-09 | 2013-12-05 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
US9095519B2 (en) | 2007-02-09 | 2015-08-04 | Alphapharm Pty Ltd | Dosage form containing two or more active pharmaceutical ingredients in different physical forms |
CN101674811B (en) * | 2007-02-09 | 2015-08-19 | 阿尔法制药有限公司 | The dosage form of the active pharmaceutical ingredient containing two or more different physical aspects |
WO2009070211A1 (en) * | 2007-11-27 | 2009-06-04 | Abbott Cardiovascular Systems Inc. | Sustained release of apo a-i mimetic peptides and methods of producing them |
WO2016050734A1 (en) * | 2014-09-30 | 2016-04-07 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Combinations of serotonin norepinephrine reuptake inhibitors and folate sources |
Also Published As
Publication number | Publication date |
---|---|
EP1663174A1 (en) | 2006-06-07 |
CA2534660A1 (en) | 2005-02-10 |
WO2005011642A9 (en) | 2005-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2341910B1 (en) | Immediate release dosage forms of sodium oxybate | |
US7229982B2 (en) | Pharmaceutical formulation | |
RU2343905C2 (en) | Solid dosed out forms including fibrat and statin | |
US7741374B1 (en) | Methods of use of fenofibric acid | |
JP4740945B2 (en) | Sustained release preparation for oral administration of HMG-CoA reductase inhibitor and method for producing the same | |
US20070014846A1 (en) | Pharmaceutical compositions comprising fenofibrate and atorvastatin | |
JP2009500317A (en) | Release characteristics improved pharmaceutical composition and process for producing the same | |
WO2006037348A1 (en) | Pharmaceutical compositions comprising fenofibrate and a statin | |
JPH07558B2 (en) | Mopidamole formulation | |
EP1581194A2 (en) | Multilayered tablet containing pravastatin and aspirin and method | |
US20120045505A1 (en) | Fixed dose drug combination formulations | |
CA2582403A1 (en) | Pharmaceutical compositions comprising fenofibrate and atorvastatin | |
EP1663174A1 (en) | Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent | |
US20150037414A1 (en) | Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin | |
EP1651194B1 (en) | Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin | |
WO2006037345A1 (en) | Pharmaceutical composition comprising fenofibrate and simvastatin | |
US20070160663A1 (en) | Single unit pharmaceutical composition comprising a mixture of fenofibrate and a modified release form of a homocysteine reducing agent | |
AU2003254428B2 (en) | Stable controlled release pharmaceutical compositions containing Fenofibrate and Pravastatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
COP | Corrected version of pamphlet |
Free format text: PUBLISHED INTERNATIONAL SEARCH REPORT (3 PAGES) REPLACED BY CORRECT INTERNATIONAL SEARCH REPORT (3 PAGES) |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2534660 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004761472 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004761472 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007160663 Country of ref document: US Ref document number: 10567407 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10567407 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004761472 Country of ref document: EP |